DFS | OS | |||||||
---|---|---|---|---|---|---|---|---|
No. | 3y-DFS(%) | HR(95 %CI) | P | 5y-OS | HR(95 %CI) | P | ||
Patients with KRAS wt | ||||||||
SLFN11high | 23 | 91.3 | 0.347(0.083–1.449) | 0.147 | 100.0 | 0.05 | ||
SLFN11low | 130 | 75.8 | 1 | 83.3 | ||||
Patients with KRAS mt | ||||||||
SLFN11high | 12 | 72.9 | 1.424(0.391–5.188) | 0.592 | 80.2 | 1.348(0.279–6.508) | 0.71 | |
SLFN11low | 51 | 83.9 | 1 | 81.9 | 1 | |||
Patients with SLFN11high | ||||||||
KRAS wt | 23 | 91.3 | 1 | 0.207 | 100.0 | 0.06 | ||
KRAS mt | 12 | 72.9 | 3.167(0.528–18.979) | 80.2 | ||||
Patients with SLFN11low | ||||||||
KRAS wt | 130 | 75.8 | 1 | 0.511 | 80.5 | 0.503 | ||
KRAS mt | 51 | 83.9 | 0.787(0.386–1.607) | 81.9 | 0.749(0.321–1.746) |